Working… Menu

Misopristol Versus Pitocin for Second Trimester Abortion

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00784797
Recruitment Status : Completed
First Posted : November 4, 2008
Last Update Posted : November 21, 2013
Information provided by (Responsible Party):
Assaf Ben Meir, Hadassah Medical Organization

Brief Summary:

Second trimester abortion can be done surgically or medically. Medical abortion with mifepristone and misopristol is one of the common protocol, but misopristol have high rate side effect. The investigators recent study proved the efficacy of pitocin after mifepristone in second trimester abortion with minimal side effects.

Working hypothesis and aims: To compare misopristol and pitocin after mifepristone preparation in second trimester in seccess rate, interval to abortion, side effects and patient satisfaction.

Condition or disease Intervention/treatment Phase
Abortion, Missed Drug: mifepristone and misopristol Drug: mifepristone and oxytocin Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 145 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Comparison Between Misopristol and Pitocin After Mifepristone Preparation for Second Trimeter Abortion
Study Start Date : January 2009
Actual Primary Completion Date : June 2012
Actual Study Completion Date : June 2012

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: pitocin
high dose pitocin drip 48 hours after mifepristone preparation.
Drug: mifepristone and oxytocin
200 mg mifepristone followed 48 hours with high dose oxytocin drip (9 unit per hour)

Active Comparator: misopristol
vaginal and oral misopristol 48 hours after mifepristone preparation.
Drug: mifepristone and misopristol
200 mg mifepristone and after 48 hours vaginal misopristol 800 mgr followed by oral misopristol 400 mgr every 3 hours for maxamum 5 doses

Primary Outcome Measures :
  1. Success rate of abortion [ Time Frame: 24 hours ]
  2. Interval to abortion [ Time Frame: 24 hours ]

Secondary Outcome Measures :
  1. Side effects [ Time Frame: 24 hours ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • midtrimester late abortion
  • midtrimester induced abortion

Exclusion Criteria:

  • placenta previa
  • infected abortion
  • rupture of membranes
  • s/p cesarean section *2 or more

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00784797

Layout table for location information
Hadassah Medical Organization
Jerusalem, Israel
Sponsors and Collaborators
Hadassah Medical Organization
Layout table for investigator information
Principal Investigator: Assaf Ben-Meir, MD Hadassah Medical Organization
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Assaf Ben Meir, MD, Hadassah Medical Organization Identifier: NCT00784797    
Other Study ID Numbers: PitocinPGMyf-HMO-CTIL
First Posted: November 4, 2008    Key Record Dates
Last Update Posted: November 21, 2013
Last Verified: November 2013
Additional relevant MeSH terms:
Layout table for MeSH terms
Abortion, Missed
Abortion, Spontaneous
Pregnancy Complications
Reproductive Control Agents
Physiological Effects of Drugs
Abortifacient Agents, Steroidal
Abortifacient Agents
Contraceptives, Oral, Synthetic
Contraceptives, Oral
Contraceptive Agents, Female
Contraceptive Agents
Contraceptives, Postcoital, Synthetic
Contraceptives, Postcoital
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Luteolytic Agents
Menstruation-Inducing Agents